David G. Loughhead

Prolonged and tunable residence time using reversible covalent kinase inhibitors

J. Michael Bradshaw, Jesse M. McFarland, Ville O. Paavilainen et al. · Nature Chemical Biology · 2015 · 422 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +5

Enzymatic inversion at saturated carbon: Nature and mechanism of the inversion of R(−) p-iso-butyl hydratropic acid

William J. Wechter, David G. Loughhead, Robert J. Reischer et al. · Biochemical and Biophysical Research Communications · 1974 · 133 citations

Biochemistry, Natural Sciences, Biocatalysis +9

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (PRN1371) for the Treatment of Solid Tumors

Ken A. Brameld, Timothy D. Owens, Erik Verner et al. · Journal of Medicinal Chemistry · 2017 · 95 citations · Full text

Drug Target, Solid Tumors, Pharmacotherapy +20

Structure−Activity Relationships for Inhibition of Inosine Monophosphate Dehydrogenase by Nuclear Variants of Mycophenolic Acid

Peter H. Nelson, Stephen F. Carr, Bruce H. Devens et al. · Journal of Medicinal Chemistry · 1996 · 49 citations · Full text

Synthesis and anthelmintic activity of 3'-benzoylurea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole

Robert J. Weikert, M.A. Emanuel, E B Fraser-Smith et al. · Journal of Medicinal Chemistry · 1991 · 47 citations